The Juvenile Macular Degeneration (Stargardt Disease) drugs in development market research report provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Juvenile Macular Degeneration (Stargardt Disease). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued products.
GlobalData tracks 40 drugs in development for Juvenile Macular Degeneration (Stargardt Disease) by 39 companies/universities/institutes. The top development phase for Juvenile Macular Degeneration (Stargardt Disease) is preclinical with 27 drugs in that stage. The Juvenile Macular Degeneration (Stargardt Disease) pipeline has 39 drugs in development by companies and one by universities/ institutes. Some of the companies in the Juvenile Macular Degeneration (Stargardt Disease) pipeline products market are: Astellas Pharma, MeiraGTx and Ray Therapeutics.
The key targets in the Juvenile Macular Degeneration (Stargardt Disease) pipeline products market include Retinal Specific Phospholipid Transporting ATPase ABCA4, Retinol Binding Protein 4, and Transthyretin.
The key mechanisms of action in the Juvenile Macular Degeneration (Stargardt Disease) pipeline product include Retinal Specific Phospholipid Transporting ATPase ABCA4 Activator with 12 drugs in Phase II. The Juvenile Macular Degeneration (Stargardt Disease) pipeline products include six routes of administration with the top ROA being Intravitreal and seven key molecule types in the Juvenile Macular Degeneration (Stargardt Disease) pipeline products market including Gene Therapy, and Small Molecule.
Juvenile Macular Degeneration (Stargardt Disease) overview
Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form of juvenile macular degeneration is Stargardt disease, an inherited autosomal recessive syndrome. Signs and symptoms include blurry or fuzzy vision; dark, empty spots in the center of vision; and difficulty reading or performing detail work. Risk factors include arteriosclerosis, hypercholesterolemia, smoking, and hypertension.
For a complete picture of Juvenile Macular Degeneration (Stargardt Disease)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
